Skip to main content
Terug
BBIO logo

BridgeBio Pharma, Inc.

Datakwaliteit: 100%
BBIO
NASDAQ Healthcare Biotechnology
€ 68,53
▼ € 1,07 (-1,54%)
Marktkapitalisatie: 13,29B
Dagbereik
€ 67,57 € 69,28
52-Weeksbereik
€ 28,33 € 84,94
Volume
1.484.761
50D / 200D Gem.
€ 72,52 / € 59,94
Vorige Slotkoers
€ 69,60

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -18,2 0,3
P/B 2,9
ROE % 3,7
Net Margin % -145,3 3,8
Rev Growth 5Y % 63,8 10,0
D/E 0,2

Koersdoel Analisten

Hold
€ 99,85 +45.7%
Low: € 83,00 High: € 157,00
Forward WPA
-€ 1,95
Omzet Sch.
920 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 8,89
€ 5,92 – € 10,87
4,1 B 6
FY2029 € 6,64
€ 4,42 – € 8,12
3,3 B 10
FY2028 € 3,70
€ 0,59 – € 6,05
2,4 B 15

Belangrijkste Punten

Revenue grew 63,82% annually over 5 years — strong growth
Negative free cash flow of -447,01M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 62,44%
Capital efficient — spends only 0,22% of revenue on capex

Groei

Revenue Growth (5Y)
63,82%
Revenue (1Y)126,26%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-65,45%
Net Margin-145,26%
Op. Margin-113,35%

Veiligheid

Debt / Equity
N/A
Current Ratio2,62
Interest Coverage-10,72

Waardering

P/E Ratio
-18,22
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 126,26% Revenue Growth (3Y) 634,64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 63,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 502,08M Net Income (TTM) -729,31M
ROE N/A ROA -77,92%
Gross Margin 94,37% Operating Margin -113,35%
Net Margin -145,26% Free Cash Flow (TTM) -447,01M
ROIC -65,45% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,62
Interest Coverage -10,72 Dividend Yield 0,00%
Valuation
P/E Ratio -18,22 P/B Ratio N/A
P/S Ratio 26,46 PEG Ratio -0,65
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 13,29B Enterprise Value 15,44B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 502,08M 221,90M 9,30M 77,65M 69,72M
Net Income -729,31M -535,76M -643,20M -481,18M -562,54M
EPS (Diluted) -3,79 -2,88 -3,95 -3,35 -3,90
Gross Profit 473,81M 218,02M 6,86M 74,21M 66,60M
Operating Income -569,09M -592,97M -607,37M -512,20M -576,63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 936,03M 919,34M 546,38M 623,04M 1,01B
Total Liabilities 3,01B 2,38B 1,89B 1,87B 1,88B
Shareholders' Equity -2,08B -1,47B -1,35B -1,25B -870,41M
Total Debt 2,73B 1,73B 1,74B 1,72B 1,73B
Cash & Equivalents 570,12M 681,10M 375,94M 376,69M 393,77M
Current Assets 753,68M 720,69M 477,59M 548,85M 888,86M
Current Liabilities 287,97M 154,40M 143,84M 121,43M 135,07M